New York State Teachers Retirement System Trims Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Teachers Retirement System cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,784 shares of the medical research company’s stock after selling 4,446 shares during the quarter. New York State Teachers Retirement System owned about 0.08% of Charles River Laboratories International worth $6,139,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after buying an additional 60,497 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after buying an additional 335,658 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock worth $227,042,000 after buying an additional 14,787 shares during the last quarter. Ariel Investments LLC grew its position in shares of Charles River Laboratories International by 18.9% during the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company’s stock valued at $197,029,000 after acquiring an additional 169,640 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Charles River Laboratories International by 17.1% during the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company’s stock valued at $190,910,000 after purchasing an additional 151,159 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent analyst reports. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Mizuho lowered their price target on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a report on Wednesday, April 9th. Finally, Barclays upped their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $171.85.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $157.12 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The stock has a 50-day simple moving average of $140.70 and a two-hundred day simple moving average of $152.50. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The firm has a market capitalization of $7.72 billion, a PE ratio of -241.72, a P/E/G ratio of 5.32 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the business earned $2.27 EPS. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).